A Prostate Specific Antigen (PSA), Total test measures the amount of PSA protein circulating in your blood. PSA is produced almost exclusively by prostate gland cells and is normally present at low levels. Because PSA can rise when prostate tissue is enlarged, inflamed, irritated, or abnormal, total PSA is used as a marker to monitor prostate health and help assess risk for conditions like BPH, prostatitis, or prostate cancer.

Total PSA testing is commonly used to screen for prostate cancer risk, especially in men over 50 and those with higher risk such as a family history. PSA can increase when prostate cancer is present, sometimes before symptoms develop. While PSA is not cancer-specific, it can flag the need for additional evaluation. Tracking PSA over time helps detect concerning changes earlier, when treatment can be more effective and less invasive.

Elevated total PSA can be caused by benign prostatic hyperplasia (BPH), prostatitis (inflammation or infection), urinary retention, or general prostate irritation. These conditions can increase PSA by enlarging prostate tissue or disrupting normal prostate architecture, allowing more PSA to enter the bloodstream. Urinary symptoms such as weak stream, frequency, nocturia, hesitancy, or pelvic discomfort may occur. A high PSA does not confirm cancer, but it warrants further evaluation.

PSA tends to be lower in younger men (often below 1.0 ng/mL) and gradually rises with age as the prostate naturally enlarges. Many labs use 4.0 ng/mL as a general upper reference limit, but age-adjusted ranges can be more meaningful. Values under 2.5 ng/mL in men under 60 are often considered reassuring. The key is interpreting PSA alongside age, symptoms, and clinical findings.

Low PSA typically reflects a small, healthy prostate with minimal cellular turnover and is generally reassuring from a prostate cancer screening perspective. Very low PSA is not usually clinically concerning. Undetectable PSA is expected in women and may be seen in men after complete prostate removal. Low PSA can also occur with medications that reduce PSA production. In most cases, stability over time is more informative than a single low reading.

Total PSA is best interpreted together with a digital rectal exam (DRE), your age, risk factors, and symptom pattern. PSA alone cannot distinguish between benign enlargement, inflammation, and cancer. Urinary symptoms - such as weak stream, frequency, incomplete emptying, nocturia, or pelvic discomfort - provide important context. PSA trends over time (rising levels, PSA velocity, and doubling time) can add insight and help guide next steps.

Because PSA can fluctuate due to benign causes, a single PSA value may be less informative than how PSA changes over time. PSA velocity (rate of rise) and PSA doubling time can help indicate whether prostate activity is stable, slowly changing with age, or increasing rapidly. Rapid or persistent rises can prompt further assessment. Trend-based surveillance helps balance early detection of aggressive disease with avoiding unnecessary testing for harmless PSA elevations.

Several factors can temporarily elevate PSA and complicate interpretation, including recent ejaculation, vigorous exercise, urinary catheterization, and prostate biopsy. PSA may also rise with inflammation or infection. Certain medications can affect PSA levels as well. Because these variables can distort results, clinicians often consider timing, symptoms, and repeat testing. Using PSA trends and combining results with DRE and clinical history improves accuracy compared with relying on one measurement.

Total PSA is widely used to monitor response to prostate cancer therapy and to track disease progression or recurrence after treatment. If PSA decreases and remains stable, it may suggest a good response. Rising PSA after therapy can signal persistent disease or recurrence and may lead to further evaluation such as imaging or biopsy. Ongoing PSA surveillance helps tailor treatment decisions and can identify changes early, before complications develop.

A high PSA does not automatically mean prostate cancer. PSA can be elevated from BPH, prostatitis, urinary retention, or other prostate irritation. When PSA is above baseline - often above 4.0 ng/mL, though age-adjusted thresholds may apply - clinicians typically assess risk factors, symptoms, and DRE findings. Further evaluation may include repeat PSA testing, imaging, and sometimes a prostate biopsy to clarify the cause of elevation.